EARLY CANCER DETECTION THROUGH NANOTECHNOLOGY-BASED BIOMARKER
DOI:
https://doi.org/10.25215/0557983827.12Abstract
Early detection of cancer is of great significance to improve survival of patients through timely intervention and reduce disease burden. Yet, traditional methods of diagnosis often do not detect cancer at its earliest stages due to the low abundance and complexity of cancer-specific biomarkers. Conventional diagnostic techniques are frequently not sensitive and specific enough for the diagnosis of cancer at its earliest stages. Nanotechnology, the manipulation of materials at the nanoscale (1-100 nm), has been proposed as a promising approach to overcome these limitations. The unique physical, optical, electrical, and magnetic properties of the nanomaterials enable the detection of cancer-associated biomarkers with high sensitivity. Cancer biomarkers are biological molecules that can be measured in blood, saliva, urine or tissues and indicate the presence or progress of cancer. These biomarkers include proteins, carbohydrates, circulating tumor DNA, microRNAs, extracellular vesicles, and other nucleic acids shed by tumor cells. Nanomaterials such as gold nanoparticles, quantum dots, magnetic nanoparticles, carbon nanotubes, and polymer dots are extensively employed for improving biomarker detection because of their amplified signal, high selectivity and large surface-area-to-volume ratio. Nanotechnology-based biosensors and liquid biopsy platforms now offer fast, accurate and minimally invasive diagnostic tools for early cancer detection and disease monitoring. Despite the difficulties in biocompatibility, standardization and clinical translation, the nanotechnology-based biomarkers hold great promise to revolutionize cancer diagnostics and enable precision oncology.Published
2026-07-03
Issue
Section
Articles
